Business Wire

IQM-QUANTUM-COMPUTERS

7.4.2022 17:23:05 CEST | Business Wire | Press release

Share
Collaboration between IQM Quantum Computers, Hebrew University of Jerusalem and Bar-Ilan University to accelerate quantum technology research.

IQM Quantum Computers , Hebrew University of Jerusalem and Bar-Ilan University have started a research cooperation on quantum technologies, with IQM providing commercial-grade quantum-computing hardware components to both universities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005722/en/

IQM, the Pan-European leader in quantum computers, Hebrew University of Jerusalem and Bar-Ilan University, among the leading universities in the world, announced today cooperation in quantum computing focused on research, exchange of know-how and quantum hardware.

The purpose of the cooperation is to provide the researchers at the Hebrew University of Jerusalem (in the group led by Professor Nadav Katz within its Physics Department and Quantum Information Science Center) and Bar-Ilan University (in the group led by Professor Michael Stern, of the Department of Physics) commercial-grade quantum-computing hardware developed by IQM. Researchers in these groups will conduct experiments using the IQM hardware and further advance scientific development.

The initiative also includes testing IQM’s qubit technology and conducting experiments based on its hardware. This long-term cooperation will result in significant scientific breakthroughs, several academic contributions and new product innovations. This is in line with IQM’s chosen strategy of providing its customers and partners direct access to hardware components.

Speaking about this announcement, Dr. Juha Vartiainen, COO and cofounder of IQM, said, “We are very happy to be working with both the Hebrew University of Jerusalem and Bar-Ilan University and look forward to a fruitful, long-term scientific and commercial cooperation. This announcement aligns well with our strategy to provide commercial-grade quantum-computing hardware to global research groups.”

“This cooperation is also a significant milestone for our cooperation with the world-class quantum ecosystem in Israel. As quantum computers develop further, the know-how developed in Israel—for example, around machine learning and quantum software—is going to become more critical in the future,” added Juha.

In the future, all parties also aim to extend the collaboration toward building full-stack quantum computers for scientific and commercial purposes in Israel.

“We are excited about this new collaboration with IQM and have already measured several consistently high-coherence IQM devices in our lab in Israel. This is just the beginning of a productive and fruitful joint venture,” shared Prof. Nadav Katz, director of HUJI’s Quantum Information Science Center.

Highly coherent controlled oscillations of IQM’s qubits measured in Israel (HUJI).

“We are proud to take part in a study that places Israel and its universities at the forefront of the global effort to develop quantum computers. The road is still long, but I believe that we at Bar-Ilan, together with our partners at the Hebrew University, will succeed in achieving groundbreaking results,” said Prof. Michael Stern.

About IQM Quantum Computers:

IQM is the Pan-European category leader in building quantum computers.

IQM provides on-premises quantum computers for supercomputing data centers and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique, application-specific, co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer, which will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has over 160 employees with offices in Paris, Bilbao, Munich and Espoo.

For more information: www.meetiqm.com

Recent IQM announcements:

- BioNTech Chief Operating Officer Dr. Sierk Poetting is to steer IQM global expansion as chairman .

- IQM continues its European expansion; the new French subsidiary will focus on IQM’s co-design customers in aviation, space and cybersecurity.

- IQM has opened its exclusive quantum fabrication facility in Finland.

- IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.

- IQM, as part of the Q-Exa consortium , is building a quantum computer in Germany that will be integrated into an HPC supercomputer for the first time.

Registered office:

IQM Finland Oy, Keilaranta 19, 02150 Espoo, Finland

About the Hebrew University of Jerusalem:

The Hebrew University of Jerusalem (HUJI) is Israel’s leading academic and research institution, serving over 25,000 students from some 80 countries on 6 campuses. Founded in 1918 by luminaries including Albert Einstein, Chaim Weizmann, Sigmund Freud and Martin Buber, HUJI is ranked in the top echelon of the world’s leading universities. To date, HU faculty and alumni have won 8 Nobel Prizes, 1 Fields Medal and 1 Abel Prize—a proud tradition of innovation and excellence.

https://en.huji.ac.il/en

About Bar-Ilan University:

Bar-Ilan University, founded in 1955, is one of Israel’s leading institutions of higher education, uniquely combining cutting-edge scientific research with education steeped in Jewish values and social responsibility. Having grown from 70 students to close to 20,500 students, its milestone achievements in the sciences and humanities and all fields of human endeavor have made an indelible imprint on the landscape of the State of Israel.

https://www.biu.ac.il/en

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release

$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in

Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation13.7.2026 11:48:00 CEST | Press release

Over 10,000 entries from 177 countries mark the highest participation in the Prize’s historySubmissions increased 32% year-on-year, reflecting sustained local led momentum for scalable global impactThrough 139 winners, the Prize has positively impacted more than 411 million lives worldwide The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, has officially closed submissions for its 2027 awards cycle, receiving an unprecedented 10,233 entries from 177 countries across its six categories of Health, Food, Energy, Water, Climate Action and Global High Schools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713519403/en/ Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation (Photo: AETOSWire) Now in its 18th year, the Prize continues to attract a diverse and growing pool of small and medium-sized enterprises, nonprofit organisations and high sc

Ant Group Open-Sources SingGuard-NSFA to Establish New Security Paradigms for Autonomous AI Agents13.7.2026 11:01:00 CEST | Press release

Ant Group’s AI Security Lab today announced the open-source release of SingGuard-NSFA, a specialized security guardrail framework designed specifically for autonomous AI agents. The framework secures agentic AI systems against operational threats like prompt injection, addressing critical vulnerabilities as AI transitions from passive content generation to active, autonomous execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712722454/en/ As AI agents rapidly move from research labs to business scenarios, the security landscape has fundamentally shifted. The explosive global adoption of open-source agent frameworks like OpenClaw, celebrated for their "one-click deployment" and "full-stack autonomy", has simultaneously exposed significant operational risks, including permission escalation and prompt injection. Industry frameworks, including the OWASP (Open Web Application Security Project) Top 10 for Agentic Applica

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 10:00:00 CEST | Press release

- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) - Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over multiple doses in this study - Pivotal Phase 3 VIVID-6 trial evaluating latarcibart’s potential to be the first targeted therapy for VWD is currently enrolling Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability t

Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 10:00:00 CEST | Press release

Combined market up 46%, led by 64% growth in cloud servicesManaged services up 21%, as companies seek cost savings to fund AI Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye